A population‐based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple‐negative breast cancer-Reference-Cited by-同舟云学术

A population‐based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple‐negative breast cancer

Published:2020-08-30 Issue:20 Volume:9 Page:7548-7557
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Brezden‐Masley Christine¹,Fathers Kelly E.²,Coombes Megan E.³,Pourmirza Behin²,Xue Cloris²,Jerzak Katarzyna J.⁴^ORCID

Affiliation:

1. Division of Medical Oncology and Hematology Faculty of Medicine University of Toronto Mount Sinai Hospital Toronto Ontario Canada

2. Department of Medical Affairs Hoffmann‐La Roche Limited Mississauga Ontario Canada

3. Market Access and Pricing Department Hoffmann‐La Roche Limited Mississauga Ontario Canada

4. Division of Medical Oncology and Hematology Faculty of Medicine University of Toronto Sunnybrook Odette Cancer Center Toronto Ontario Canada

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3038

Reference47 articles.

1. The current state of breast cancer classification

2. Triple-Negative Breast Cancer

3. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

4. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

5. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Examining breast cancer screening recommendations in Canada: The projected resource impact of screening among women aged 40–49;Journal of Medical Screening;2024-08-06

2. Real-World Treatment Patterns, Clinical Outcomes, Healthcare Resource Utilization, and Costs in Advanced Hepatocellular Carcinoma in Ontario, Canada;Cancers;2024-06-15

3. Direct and Indirect Costs of Breast Cancer and Associated Implications: A Systematic Review;Advances in Therapy;2024-06-04

4. Neoadjuvant chemotherapy for triple-negative and Her2 +ve breast cancer: striving for the standard of care;Breast Cancer Research and Treatment;2024-04-27

5. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with early triple negative breast cancer;Breast Cancer Research and Treatment;2024-01-19